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Available online 13 April 2016Background: Both ﬁsh (FO) and ﬂaxseed oils (FLX) are n-3 polyunsaturated fatty acids (PUFA). Fish oil contains
long chain while FLX contains essential n-3 PUFA. We demonstrated that FO altered insulin secretion and resis-
tance in polycystic ovary syndrome (PCOS)women but FLX did not. Surprisingly, the effects of FOwere similar to
those of the n-6 PUFA-rich soybean oil (SBO). Since increased branched chain (BCAA) and aromatic amino acids
(AA) affect insulin secretion and resistance, we investigated whether FO, FLX and /or SBO affect plasma metab-
olites, especially AA.
Methods and ﬁndings: In this six-week, randomized, 3-parallel arm, double-blinded study, 54 women received
3.5 g/day FO, FLX or SBO. In 51 completers (17 from each arm), fasting plasma metabolites were measured at
the beginning and at the end.
As compared to FLX, FO and SBO increased insulin response and resistance as well as several BCAA and aromatic
AA. Pathway analysis indicated that FO exerted the largest biochemical impact, affecting AA degradation and bio-
synthesis, amine, polyamine degradation and alanine, glycine, L-carnitine biosynthesis and TCA cycle, while FLX
had minimal impact affecting only alanine biosynthesis and L-cysteine degradation.
Conclusion: Effects of FO and SBO on plasma AAwere similar and differed signiﬁcantly from those of the FLX. The
primary target of dietary PUFA is not known. Dietary PUFAmay inﬂuence insulin secretion and resistance directly
and alter plasma AA indirectly. Alternatively, as a novel concept, dietary PUFAmay directly affect AAmetabolism
and the changes in insulin secretion and resistance may be secondary.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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PCOS1. Introduction
Polyunsaturated fatty acids (PUFA) are powerful modulators of lipid
and glucosemetabolism. Their actions are considered to be class speciﬁc
as the PUFA from omega-3 (n-3) vs. n-6 have different and usually
opposing actions. For example, n-3 PUFA lower serum triglycerides
while n-6 PUFA lower total cholesterol and low density lipoprotein
(LDL)-cholesterol [1]. Experimental studies suggest that n-3 PUFA de-
crease, whereas n-6 PUFA increase insulin secretion; and both n-3 and
n-6 PUFA increase insulin sensitivity [2]. Although theﬁndings of exper-
imental vs. clinical studies agree on lipid metabolism, they vary a great
deal regarding glucose homeostasis.gy, Diabetes and Metabolism,
e G400, Sacramento, CA 95817,
.
pen access article under the CC BY-NSigniﬁcant gaps in knowledge exist regarding the biological effects
of PUFA. For example, no distinction has beenmade between the effects
of long-chain vs. essential n-3 PUFA. Flaxseed oil is a rich source of the
essential n-3 PUFA α-linolenic acid (ALA, 18:3) while ﬁsh oil contains
the long chain n-3 PUFA eicosapentanoic acid (EPA, 20:5) and
docosahexanoic acid (DHA, 22:6). Although ALA can be converted to
EPA in vivo, this is very inefﬁcient in humans [3]. Despite that, in clinical
practice these oils are used interchangeably. However, the choice of the
exact type of oil used is important because ALA ismetabolized different-
ly than EPA and DHA. While ALA competes with the n-6 essential PUFA
linoleic acid (LA, 18:2) forΔ6 desaturase and interfereswith production
of arachidonic acid (AA, 20:4), EPA and DHA compete at more distal
steps at the cyclooxygenase and lipooxygenase [4].
We had compared the effects ﬁsh, ﬂaxseed and soybean oils on
glucose homeostasis in polycystic ovary syndrome (PCOS) [5]. This
syndrome provides an excellent clinical model because the affected
young women are insulin resistant; at least 50% of PCOS patients
have metabolic syndrome; one third of patients have glucoseC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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age of 40 years. Hyperinsulinemia aggravates reproductive dysfunc-
tion by stimulating ovarian androgen production, by reducing sex
hormone binding globulin (SHBG); thus by increasing bioavailable
testosterone. Treatment of insulin resistance increases fertility in
PCOS [7].
We assessed insulin resistance and secretion using oral and frequent-
ly sampled intravenous glucose tolerance tests (OGTT and FS-IGT, re-
spectively). Unexpectedly, ﬁsh and soybean oils caused similar changes
in glucose homeostasis; furthermore, their effects were distinctly differ-
ent than those of ﬂaxseed oil [6]. These observations challenged the
widely accepted concept that “the biological effects of PUFA are speciﬁc
To their omega class” The similarities between the effects of n-3 PUFA
rich ﬁsh oil and n-6 PUFA rich soybean oil suggested complex regulatory
mechanisms.
Several studies employing the metabolomics technology suggest
perturbations of branched chain amino acid (BCAA) and aromatic
AA metabolism in insulin resistance and obesity [8]. Obese, insulin
resistant individuals demonstrated a characteristic increase in
fasting plasma concentrations of BCAA: (valine, isoleucine, leucine)
and their catabolic byproducts such as glutamate, α-ketoglutarate,
C3 and C5 acylcarnitines [9–12]. We also found direct correlations
between serum BCAA ad insulin resistance parameters in women
with metabolic syndrome [13]. Similar ﬁndings were observed in a
subpopulation of the Framingham Cohort where a few AA (leucine,
isoleucine, valine, phenylalanine, tyrosine) could predict the ﬁve-
fold increase in type 2 DM [12]. Therefore, we investigated the effects
of ﬁsh, ﬂaxseed and soybean oils on BCAA and other primary metab-
olites in PCOS.Fig. 1. Consort2. Research design and methods
2.1. Subjects
The study was approved by the Institutional Review Board of
University of California, Davis and registered with the NIH. The subjects
were recruited between September 2007 and February 2010, and were
included in the study after signing the written informed contents. Clin-
ical characteristics of the patients, the study protocol, clinical studies
and the results have been reported previously [6].
Women between the ages 20 and 45 years and with a body mass
index (BMI) of 25–45 kg/m2, fulﬁlling the NIH criteria for PCOS by
having ovarian dysfunction (amenorrhea; no periods for N6 months,
or oligomenorrhea: b6 periods/year; clinical or laboratory evidence
for hyperandrogenemia; total testosterone N54 ng/dl or free testoster-
one N9.2 pg/ml), along with the absence of any confounding clinical
pathology (i.e. Cushing's disease, 21 hydroxylase deﬁciency or
prolactinoma) were recruited [7]. Patients were excluded if they used
oral contraceptives, anti-androgenic medications, insulin sensitizers,
d-chiro inositol, lipid lowering drugs during the preceding twomonths;
had diabetesmellitus, untreated hypothyroidismor thyroid disease, and
any other systemic illness such as renal, hepatic, and gastrointestinal
disease; smoke; or drink N2 alcoholic drinks per week.
2.2. Consort statement
As shown in Fig. 1, two hundred and twenty-six PCOS patients were
assessed for eligibility; 159 subjects either failed to meet the inclusion/
exclusion criteria (n= 96), refused to participate (n= 41) or had otherdiagram.
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randomized using the http://www.randomizer.org/form.htm. Five sub-
jects left before receiving any intervention; the remaining received ei-
ther ﬁsh oil (n = 21), soybean oil (n = 18) or ﬂaxseed oil (n = 23).
Fifty-four patients completed the 6-week study (17 in the ﬁsh oil arm,
18 in the soybean oil arm and 19 in the ﬂaxseed oil arm). Plasma sam-
ples from ﬁfty-one patients (17 in each arm; 35 White, 5 African
American, 5 Hispanic, 4 Asian, 1 American Indian and 1 other) were an-
alyzed for the plasma metabolites and reported in this manuscript.
2.3. Study design
This was a six-week long, randomized, 3-parallel arm, double-
blinded study. Fish oil and ﬂaxseed oil supplements contained approxi-
mately the same amount of total n-3 PUFA in 6 capsules (3.5 g). Each
ﬂaxseed oil capsule contained 545 mg ALA (Barleans Organic Oils,
Ferndale,WA); ﬁsh oil contained 358mg EPA plus 242mgDHA (Nordic
Naturals, Watsonville, CA). Soybean oil (Nordic Naturals, Watsonville,
CA), whichwas recommended as placebo by the Product QualityWork-
ing Group (PQWG) of the NCCAM, contained 200 mg oleic acid, 429mg
LA, 57 mg ALA and very small amounts of palmitic and stearic acids.
2.4. Data collection
Data were obtained at the beginning and at the end of the study at
the CTSC-CCRC of the University of California, Davis. Themethodologies
for the collection of nutritional intake, anthropometrics measurements,
OGTT, IVGTT, biochemical measurements and calculations have been
reported in detail previously [6].
2.5. Metabolomic studies (GC-TOF MS-based)
Pyridine, acetonitrile, isopropanol,methoxyamine hydrochloride, N-
methyl-N-trimethylsiliyl triﬂuoroacetamide (MSTFA) and all the stan-
dards were obtained from Sigma Aldrich, USA.
20 μl plasma was extracted by 1 mL degassed cold (−20 °C) aceto-
nitrile: isopropanol:water (3:3:2; v/v/v) solution. 500 μl of the superna-
tant was evaporated to dryness. Triglycerides and lipids were removed
by adding 500 μl of ACN:Water (1:1) and evaporating the supernatant.
The dried extracts were derivitazed in two steps with methoxyamine
hydrochloride followed by silylation with N-methyl-N-trimethylsiliyl
triﬂuoroacetamide (MSTFA). A fatty acid methyl ester (FAME) mixture
of C8 through C30was added to the derivatized samples as retention in-
dicesmarkers. Derivatized sampleswere analyzed byGas Chromatogra-
phy–Mass Spectrometry (GC–MS) on an Agilent 6890 GC-LECO Pegasus
III TOF equipped with a Cooled Injection System (CIS4), an Automated
Linear Exchange system (ALEX), and a Multi Purpose Sampler (MPS,
all Gerstel). The injector was run with an initial temperature of 50 °C
and ramped to 275 °C at a rate of 12 °C/s. The injection volume was
0.5 μL and injector mode was splitless with purge time 25 s. GC condi-
tions were set with a programmed oven temperature of 50 °C, held
here for 1 min, then ramped to 330 °C at a rate of 20 °C/min, held at
330 °C for 5 min; with carrier gas ﬂow rate at 1 ml/min. The GC column
was RTX-5 MS, 30 m long, 0.25 mm i.d. ×0.25 μm ﬁlm with 10 m inte-
grated guard column. The transfer line and ion source temperature
were set at 280 °C and 250 °C, respectively. Solvent delay was adjusted
to 4.5 min and MS acquisition was optimized to 17 spectra per scan,
using a mass range of 80 to 500 m/z. The Multichannel Plate (MCP)
detector voltage was adjusted to 1850 V.
2.6. Data processing
Chromatogram acquisition, data handling, automated peak
deconvolution and export of spectra were automatically performed
by the Leco ChromaTOF software (v2.32). Peak picking was achieved
in ChromaTOF (v2.32) at signal/noise levels of 5:1 throughout thechromatogram, with baseline subtraction just above the noise level,
no smoothing, 3-s default peak widths, automatic mass-spectral
deconvolution and peak detection and export of result spectra as *.csv
ﬁles, in addition to export of raw data in open-access *.cdf formats.
Data were further processed using the algorithms in the open-source
BinBase metabolome database [14]. This algorithm used the settings:
validity of chromatogram (b10 peaks with intensity N107 counts s−1),
), unbiased retention index marker detection (MS similarity N800 and
exceeding thresholds for ion-ratio abundances for high m/z marker
ions), and retention index calculation by 5th-order polynomial
regression.
Spectra were cut to 5% base peak abundance, and matched to data-
base entries from most- to least-abundant spectra, using the following
matching ﬁlters: retention index window ±2000 units (equivalent to
about ±2 s retention time), validation of unique ions and apex masses
(unique ion must be included in apex masses and present at N3% of
base-peak abundance), mass spectrum similarity that must ﬁt criteria
dependent on peak purity and signal/noise ratios, optional ion-ratio set-
tings to distinguish peaks with high similarity, and a ﬁnal isomer ﬁlter
(annotating the isomer spectrumwith the closest RI ﬁt). Signal intensi-
ties were reported as peak heights, using the unique ion as default, un-
less an alternative quantiﬁcation ion was manually set in the BinBase
administration software Bellerophon. All known artifact peaks—such
as internal standards, column bleed, plasticizers or reagent peaks—were
assigned by BinBase but not exported for further statistical calculations.
Metabolites were identiﬁed using the Fiehnlib libraries consisting of
N1000 authentic compounds and referenced using PubChem identiﬁers
[15]. Daily quality controls were used comprising method blanks and
ﬁve-point calibration curve samples of 31 pure reference compounds,
which were repeatedly analyzed over the full analytical sequence, in
addition to injection of one QC sample for every 10 biological samples.
A quantiﬁcation report table was produced for all database entries
that were positively detected in N50% of the samples of a study design
class (as deﬁned in the miniX database). This procedure results in
10–30%missing values, which could be caused by true negatives (com-
pounds below the detection limit) or false negatives (compounds pres-
ent but did not match quality criteria in the BinBase algorithm).
A subsequent post-processing module was employed to automati-
cally replace missing values from the *.cdf ﬁles with the following
parameters: for each positively detected metabolite, the average reten-
tion time was calculated for the day of analysis. Subsequently, for each
chromatogram and each missing value, intensity of the quantiﬁcation
ion at this retention time was extracted by seeking its maximum value
in a retention-time region of ±1 s and subtracting the minimum
(local background) intensity in a retention-time region of ±5 s around
the peak maximum. The resulting report table, therefore, did not
contain anymissing values. Replaced values were labeled as ‘lower con-
ﬁdence’ by color-coding.
2.7. Data normalization
Resultswere normalized by calculating the sum intensities of all iden-
tiﬁed compounds for each sample and dividing all data associated with a
sample by the corresponding metabolite sum. The resulting data were
multiplied by the average sum of all identiﬁed metabolites detected in
the study (total average metabolome transformation)—disregarding un-
known metabolites because these might potentially also represent
artifacts. Intensities of identiﬁed metabolites with more than one peak
(e.g. for the syn- and anti-forms of methoximated reducing sugars or
amino acids with different derivatization status of amine groups) were
summed to only one value in the transformed data set. The original
non-transformed data set was retained for retrospective analysis. When
comparing classes of samples with biologically different sum concentra-
tions of identiﬁed metabolites (p b 0.05), these class averages were
used formean transformations. Result ﬁles were exported and processed
by metabolomics BinBase database [14].
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For the clinical data, the SAS software, version 9.1 (SAS Institute Inc.,
Cary, NC) was used. Descriptive statistics were calculated for each out-
come. The datawere log-transformed in order to improve the normality
of residuals and homoscedasticity of errors where appropriate before
analysis. Paired t-test was performed to determine the signiﬁcance
of within-group change. Inter-group comparisons were performed
by analysis of covariance (ANCOVA), adjusted for the baseline values.
When the overall difference among the groups was signiﬁcant in
ANCOVA, post-hoc pair wise group comparisons were performed
using the Bonferroni multiple comparisons procedure to determine
the signiﬁcant differences. The longitudinal trajectories for changes in
glucose and insulin during OGTT were estimated by repeated measures
analysis of variance. Individual trajectories for changes in glucose and
insulin were estimated from linear random-effects models. Each ob-
served level was entered as the dependent variable. Treatment, time,
and treatment x time interaction term were entered as independent
variables. The coefﬁcients for the interaction term were to estimate
the additional changes in glucose and insulin level over time associated
with treatment. To account for between-subject heterogeneity in the
change of glucose or insulin, intercept and time were modeled as ran-
dom effects. The 51 subjects included in the analysis had no missing
endpoint values. A two-sided p-value b0.05 was considered signiﬁcant.
For the metabolomics data, to determine the baseline relationships
among themetabolites and the clinical markers fasting plasmametabo-
lites and several measures of insulin resistance and insulin secretion
obtained from 79 PCOS patients were analyzed using multivariate re-
gression splines (MARS). Model variables were automatically selected
by theMARS algorithm fromapool of 22 nitrogenous compounds (most-
ly amino acids). In order to avoid over-ﬁtting the algorithm pruned the
number of variables to use only a maximum of 11 metabolites.
The metabolic pathways affected by ﬁsh, ﬂaxseed and soybean oil
treatments were determined using the PathwayTools software (version
17.0) from SRI International [16]. The HumanCyc, version 17.1was used
as reference [17]. The compounds which changed from the baselineTable 1
Effects of ﬁsh, ﬂaxseed and soybean oil treatments on anthropometric parameters, glucose hom
Fish oil (n = 17)
Baseline Δ B
Age (years) 31.7 ± 7.8 – 29.
Weight (kg) 100.0 ± 21.4 0.2 ± 0.8 94.
BMI (kg/m2) 36.3 ± 7.8 0.3 ± 0.8 35.
Glucose (mmol/L) 5.5 ± 0.7 −0.1 ± 0.9 5.
Insulin (pmol/L) 153.5 ± 71.7 4.9 ± 63.1 172.
HgBA1 (%) 5.5 ± 0.4 −0.1 ± 0.1⁎ 5.
Adiponectin (ng/ml) 7.5 ± 4.1 1.0 ± 3.7 8.
Leptin (ng/ml) 29.8 ± 14.4 −0.4 ± 10.3 27.
HOMA 5.46 ± 2.8 0.10 ± 2.5 5.9
ISIMatsuda 2.4 ± 1.5 −0.5 ± 0.9⁎ 2.
AUCGluc (mmol/L·2 h) 15.7 ± 2.5 0.8 ± 2.3 15.
AUCInsulin (pmol/L·2 h) 1660 ± 944 326 ± 800b 192
AIRg (pmol/L) 893 ± 705 −107 ± 231†,a 62
DI 1212 ± 779 229 ± 231 95
SI 1.5 ± 1.0 0.2 ± 1.2 1.
Triglyceride (mmol/L) 1.5 ± 0.6 −0.3 ± 0.4⁎ 1.
Total-C (mmol/L) 5.0 ± 0.9 0.2 ± 0.7 4.
LDL-C (mmol/L) 3.3 ± 0.7 0.2 ± 0.9 2.
HDL-C (mmol/L) 1.1 ± 0.2 0.1 ± 0.2 1.
ApoB (g/L) 82.8 ± 20.9 3.4 ± 19.3 65.
hs-CRP (mg/L) 3.6 ± 3.2 −0.4 ± 2.4 3.
Inter-group comparisons were performed by analysis of covariance (ANCOVA), adjusted for th
pair wise group comparisons were performed using the Bonferroni multiple comparisons proc
⁎ p b 0.05 for the change from the baseline, as analyzed by paired t-test.
† p b 0.1 for the change from the baseline, as analyzed by paired t-test.
a p b 0.05 as compared to the change with ﬂaxseed oil.
b p b 0.05 as compared to the change with soybean oil.(two tails student t-test p-value b0.1), were used for pathway enrich-
ment analysis. A minimum of 3 matches (hits) between the signiﬁcant
compound list and the reference pathway were required. Raw enrich-
ment p-values were adjusted for multiple testing by Benjamini &
Hochberg False Discovery Rate (FDR) [18]. A pathway with a FDR p-
value b0.01 was considered enriched. A network of signiﬁcant com-
pounds from the three oil treatments was overlaid on a KEGG reaction
network [19,20].
3. Results
3.1. Relationships between metabolites and clinical measures of insulin
resistance and secretion
Themultivariate regression splines (MARS) analysis indicated that 7
to 11 metabolites which provided predictive associations with insulin
resistance and pancreatic function were BCAA, aromatic AA and other
nitrogenous compounds (r2 = 0.70–0.86). A model built only on BCAA
and aromatic AA alone was not as predictive (r2 for AIRg: 0.48 and
fasting glucose: 0.24).
3.2. Changes in glucose homeostasis, plasma lipids and hs-CRP (Table 1
and Fig. 2)
For glucose homeostasis, ﬁsh and soybean oils shared several effects
which differed from those of ﬂaxseed oil. Within-group, ﬁsh oil de-
creased HGBA1c (Δ:−0.1 ± 0.1, p = 0.003) and the Matsuda's insulin
sensitivity index (Δ:−0.5 ± 0.9, p = 0.038); and tended to decrease
early insulin secretion (AIRg;Δ:−107±231, p=0.087) but overall in-
sulin secretion did not decrease (AUCInsulin; Δ: 326 ± 800 pmol/L·2 h,
p = 0.116). Between-group comparisons indicated that when com-
pared to ﬂaxseed oil, ﬁsh oil decreased early insulin secretion (AIRg:
p = 0.024) but tended to increase cumulative insulin secretion
(AUCInsulin: p = 0.062) (Fig. 2). The disposition index (DI) tended to
be higher in ﬁsh oil treatment as compared to soybean oil (p = 0.059).eostasis and cardiovascular risk markers (mean ± SD; Δ: change from the baseline).
Flaxseed oil (n = 17) Soybean oil (n = 17)
aseline Δ Baseline Δ
4 ± 6.6 – 28.9 ± 4.1 –
1 ± 33.8 0.6 ± 1.6 90.0 ± 23.5 0.6 ± 1.6
0 ± 10.3 0.2 ± 0.8 33.2 ± 7.4 0.1 ± 3.3
2 ± 0.3 0.2 ± 0.5 4.9 ± 0.5 0.1 ± 0.5
9 ± 162.2 15.3 ± 160 122.2 ± 68.9 9.7 ± 34.2
5 ± 0.4 −0.1 ± 0.4 5.4 ± 0.4 0.1 ± 0.4
0 ± 4.9 −0.4 ± 2.1 6.5 ± 4.9 −0.3 ± 1.6
1 ± 13.6 1.4 ± 4.2 28.1 ± 14.0 2.5 ± 12.0
1 ± 6.1 0.9 ± 6.5 3.9 ± 2.4 0.4 ± 1.9
5 ± 1.7 −0.1 ± 0.8 3.3 ± 1.7 −0.4 ± 1.0
9 ± 3.0 0.8 ± 2.8 14.8 ± 2.5 1.6 ± 2.3⁎
4 ± 1373 −146 ± 717 1292 ± 800 167 ± 458
7 ± 334 40 ± 210 669 ± 367 −119 ± 264†
6 ± 713 11 ± 532 1784 ± 1798 −684 ± 1761
6 ± 0.9 1.4 ± 1.2 3.1 ± 3.1 −0.7 ± 0.4
6 ± 1.0 −0.3 ± 0.5⁎ 1.4 ± 0.7 0.7 ± 0.4
7 ± 1.0 0.3 ± 7 4.9 ± 0.7 −0.3 ± 1.1
8 ± 0.7 0.2 ± 0.4 2.9 ± 0.8 −0.3 ± 0.9
2 ± 0.33 0 ± 0.21 1.2 ± 0.3 0 ± 0
0 ± 51.5 −1.0 ± 45.9 76.8 ± 19.4 0.7 ± 14.0
8 ± 2.9 −0.1 ± 3.2 2.6 ± 2.5 0.1 ± 1.2
e baseline values. When the overall difference among the groups was signiﬁcant, post-hoc
edure to determine the signiﬁcant differences.
Fig. 2. Effects of ﬁsh oil (FO), ﬂaxseed oil (FLX) and soy bean oil (SBO) on early response
(AIRg) measured by frequently sampled intravenous glucose tolerance test and on the
cumulative insulin response measured by oral glucose tolerance test (AUCGlucose:
pmolU/ml·2 h), shown as changes as compared to the pretreatment values (means ±
SD; n = 17 in each treatment arm, b: p b 0.05 as compared to soybean oil). Paired t-test
was performed to determine the signiﬁcance of within-group change. Inter-group
comparisons were performed by analysis of covariance (ANCOVA), adjusted for the
baseline values. When the overall difference among the groups was signiﬁcant in
ANCOVA, post-hoc pair wise group comparisons were performed using the Bonferroni
multiple comparisons procedure to determine the signiﬁcant differences.
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and they differed from the effects of soybean oil. Plasma triglyceride
decreased with both ﬁsh oil (Δ:−0.3 ± 0.4 mmol/L, p = 0.015) and
ﬂaxseed oil (Δ: −0.3 ± 0.5 mmol/L, p = 0.018). Between group
comparisons showed that the effects of ﬁsh oil on triglyceride and
LDL-cholesterol tended to differ from the effects of soybean oilTable 2
Effects of ﬂaxseed, ﬁsh and soybean oils on serummetabolites (expressed as quantiﬁer peak h
Fish oil (n = 17)
Baseline Δ
BCAA & essential Isoleucine 26,678 ± 4346 5012 ± 5541⁎,a 3
Leucine 46,568 ± 6844 8250 ± 11,380⁎ 5
Valine 83,560 ± 12,332 15,951 ± 19,284⁎,a 9
Lysine 39,275 ± 5554 4651 ± 8419 4
Aromatic AA Phenylalanine 13,450 ± 2016 1381 ± 3327 1
Tyrosine 3678 ± 581 270 ± 606
Tryptophan 27,201 ± 2940 2146 ± 5686 3
Sulfur AA Methionine 1364 ± 808 205 ± 647
Meth. sulfoxide 2916 ± 1105 712 ± 775⁎
Cysteine 1499 ± 570 −860 ± 548⁎,b
Cystine 2544 ± 437 −1567 ± 462⁎,b
1C Glycine 97,499 ± 12,398 25,763 ± 24,277a 11
Serine 26,831 ± 7673 7833 ± 9553⁎,a 3
Glutamic acid 22,635 ± 6032 4028 ± 5203a 2
Glutamine 15,770 ± 9001 2321 ± 5884b 1
Non-Es Alanine 156,533 ± 32,486 13,995 ± 32,828 15
Proline 47,965 ± 11,792 17,534 ± 17,771⁎ 5
Others Urea 234,794 ± 5489 −16,224 ± 72,117 24
Uric acid 11,992 ± 3200 754 ± 3740 1
Uridine 112 ± 45 41 ± 82
3-βOH butyrate 8920 ± 9001 −4899 ± 9248
Inter-group comparisons were performed by analysis of covariance (ANCOVA), adjusted for the
pair wise group comparisons were performed using the Bonferroni multiple comparisons proc
⁎ p b 0.05 for the change from the baseline, as analyzed by paired t-test.
a p b 0.05 as compared to the change with ﬂaxseed oil;
b p b 0.05 as compared to the change with soybean oil.(inter-group p = 0.055 for Δ triglyceride and p = 0.081 for Δ LDL-
cholesterol).3.3. Changes in fasting plasma amino acids (Table 2 and Fig. 3)
Fish and soybean oils increased several AA in the plasma. As com-
pared to the baseline, ﬁsh oil increased isoleucine (p = 0.006), leucine
(p = 0.035), valine (p = 0.019), methionine (p = 0.013), serine
(p= 0.024) and proline (p= 0.007) Soybean oil also increased isoleu-
cine (p = 0.001), valine (p = 0.016), glycine (p = 0.023) and proline
(p= 0.045) They both decreased cysteine and cysteine. Increases in va-
line and isoleucine correlated with the increases in insulin response
during OGTT (for valine, insulin at 60 min: r = 0.321, p = 0.022; at
90 min: r = 0.353, p = 0.011; AUCInsulin: r = 0.388, p = 0.005; for iso-
leucine, insulin at 90 min: r = 0.352, p = 0.011; AUCInsulin: 0.319, p =
0.022).
Flaxseed oil did not affect plasma AA levels, except decreasing cyste-
ine (p = 0.016) and cystine (p = 0.001).3.4. Metabolic pathways and networks affected by ﬁsh, ﬂaxseed and soy-
bean oil treatments
Fish oil exerted the biggest biochemical impact, affecting AA degra-
dation (15 hits, p = 2 × 10−7); AA biosynthesis (13 hits, p =
3 × 10−6); C1 compound utilization (7 hits, p = 6 × 10−4); amine
and polyamine degradation (7 hits, p = 2 × 10−3); purine nucleotide
degradation (5 hits, p = 2 × 10−3); TCA cycle (4 hits, p = 2 × 10−3);
and alanine, glycine, L-carnitine biosynthesis. Soybean oil also affected
AA degradation (12 hits, p = 2 × 10−5) or AA acid biosynthesis (11
hits, p = 4 × 10−5). Flaxseed oil had minimal impact, affecting only al-
anine biosynthesis and L-cysteine degradation (each 3 hits; p = 0.002
for both).
Using enrichment analysis, it is difﬁcult to distinguish whether the
synthesis or the degradation pathway is affected because the same com-
pounds are involved in both pathways. However, increases in speciﬁc
degradation compounds and the higher number of hits on degradationeight means ± SD).
Flaxseed oil (n = 17) Soybean oil (n = 17)
Baseline Δ Baseline Δ
0,792 ± 5640 177 ± 6428 29,001 ± 3364 4757 ± 44,902⁎
4,082 ± 8522 −685 ± 13,363 51,347 ± 6444 7290 ± 7512
7,055 ± 15,998 1758 ± 16,175 97,313 ± 9100 8854 ± 9124⁎
7,970 ± 11,256 −1666 ± 13,342 42,997 ± 7995 1385 ± 1427
6,946 ± 3834 −1416 ± 4354 15,024 ± 2569 1250 ± 1291
4002 ± 891 −101 ± 808 3719 ± 763 81 ± 82
2,698 ± 5822 193 ± 6259 32,418 ± 5529 −623 ± 643
2230 ± 816 302 ± 1056 2065 ± 1113 570 ± 713⁎
2490 ± 936 −63 ± 1233 2596 ± 1006 329 ± 750
1447 ± 515 −496 ± 569⁎ 1504 ± 709 −448 ± 458⁎
2313 ± 375 −680 ± 482⁎ 2143 ± 750 −486 ± 503⁎
8,891 ± 25,440 5949 ± 21,923 105,798 ± 13,610 13,456 ± 13,870⁎
3,660 ± 6329 −737 ± 9471 31,522 ± 4824 3443 ± 3550
4,052 ± 7426 −1978 ± 8630 17,068 ± 7982 −1284 ± 1324
9,576 ± 7855 3175 ± 8630 27,978 ± 14,942 769 ± 792
9,479 ± 27,885 −666 ± 28,425 148,432 ± 25,918 10,227 ± 10,543
1,408 ± 11,339 7959 ± 18,550 51,626 ± 8353 8827 ± 9100⁎
2,284 ± 42,579 −13,799 ± 38,147 255,009 ± 55,765 −30,644 ± 31,587
4,303 ± 3146 1089 ± 3224 14,573 ± 3303 1155 ± 1192
138 ± 33 1 ± 58 195 ± 49 12 ± 12
7640 ± 4441 54 ± 6123 5490 ± 2573 3101 ± 2989
baseline values. When the overall difference among the groups was signiﬁcant, post-hoc
edure to determine the signiﬁcant differences.
Fig. 3. Effects of ﬁsh oil (FO), ﬂaxseed oil (FLX) and soy bean oil (SBO) on fasting plasma amino acids, shown as changes as compared to the pretreatment values (mean ± SD; n= 17 in
each treatment arm; *: p b 0.05 for the change from thebaseline; a: p b 0.05 as compared toﬂaxseed oil). Paired t-testwasperformed to determine the signiﬁcance ofwithin-group change.
Inter-group comparisonswere performed by analysis of covariance (ANCOVA), adjusted for the baseline values.When the overall difference among the groupswas signiﬁcant in ANCOVA,
post-hoc pair wise group comparisons were performed using the Bonferroni multiple comparisons procedure to determine the signiﬁcant differences.
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primarily AA degradation.4. Discussion
Polyunsaturated fatty acid supplements used in this study caused
modest but signiﬁcant changes in glucose homeostasis, plasma lipids
and, unexpectedly, amino acid metabolism. Use of metabolomics pro-
vided a novel perspective for the understanding of the effects of PUFA
on glucose homeostasis. Unexpectedly, long chain n-3 PUFA rich ﬁsh
oil and n-6 PUFA rich soybean oil showed similarities in their effects
on glucose homeostasis, plasma AA and nitrogenous compounds. On
the other hand, ﬂaxseed oil, which also belongs to n-3 class, behaved
distinctly different than ﬁsh oil.
It is generally accepted that themetabolic effects of dietary PUFA are
class-speciﬁc: Here we demonstrated that their effects on lipid metabo-
lismmay be class-speciﬁc because both ﬁsh and ﬂaxseed oils decreased
plasma triglyceride. However, changes seen in glucose homeostasis
could not be explained on the basis of n-3 vs. n-6 classiﬁcation.
We have found that ﬁsh oil decreased theMatsuda index, suggesting
that insulin resistance increased. Although it iswidely stated that ﬁsh oil
increases insulin sensitivity, this is based on studies in experimental an-
imals [21]. The studies in humans have shown either unchanged or in-
creased insulin resistance [22–24]. Findings of experimental vs. clinical
studies on pancreatic insulin secretion differ as well. The experimental
studies indicate that both the essential and the long chain n-6 PUFA
stimulate insulin secretion [25]. Thus n-3 PUFA are expected to decrease
insulin secretion by competing with n-6 PUFA [26]. Insulin secretion
occurs in two phases: early and late. As pancreas starts to fail, the
early insulin secretion decreases, the late phase becomes more promi-
nent. We found that both n-6 PUFA rich soybean oil and long chain n-
3 rich ﬁsh oil tended to decrease the early insulin secretion (AIRg) but
increased the late response and overall insulin secretion.
Several clinical studies investigated the effects of ﬁsh oil on blood
glucose levels. Although individual studies showed variable changes in
insulin secretion and insulin sensitivity, the overall glycemic control
did not change [27]. We found that ﬁsh oil did not reduce glucose dis-
posal (DI) possibly because of the compensatory increase in late insulin
secretion; and DI was higher during ﬁsh oil treatment as compared to
soybean oil. This may explain the decrease in HgBA1c during ﬁsh oil
supplementation.In the literature, the variability in the effects of n-3 PUFA on glucose
homeostasis has been attributed to the differences in the dose of the
supplements, subject populations and underlying disease states. How-
ever, the effects of n-3 PUFA on lipid metabolism have been quite con-
sistent even though the study conditions have been as variable [1,28].
This raises the possibility that the effects of PUFA on lipid metabolism
may be direct and class-speciﬁc; whereas, their effects on glucose
homeostasis may be much more complex.
The recent literature emphasized that serum BCAA, essential AA and
aromatic AA related to various aspects of glucose homeostasis [12,29,
30]. We reported similar results in a group of women with metabolic
syndrome who did not have PCOS [13]. In this study a battery of AA
and nitrogenous compounds showed predictive associations with
fasting glucose, fasting insulin, HOMA, AUCInsulin and AIRg as well.
Moreover addition, ﬁsh and soybean oils which affected glucose ho-
meostasis also increased BCAA leucine, isoleucine and valine, while ﬂax-
seed oil, which did not affect glucose homeostasis, did not increase
BCAA either. Regardless the treatment, the increases in plasma valine
and leucine correlated directly with the increase in insulin response
during OGTT. There may be two mechanisms: First, BCAA may have
caused insulin resistance which then led to compensatory increase in
insulin response. Second, BCAA may have acted as insulin secretagouge
in the pancreas potentiating insulin response to glucose.Wehave previ-
ously demonstrated that whey protein, a rich source of essential and
BCAA, stimulated insulin secretion in PCOS without changing plasma
glucose levels [31].
We demonstrated that ﬁsh oil increased three out of four BCAA by
18% to 19% and soybean oil increased them by 9% to 16% while ﬂaxseed
oil did not affect plasma AA, AA metabolism or glucose homeostasis.
Pathway analysis indicated that the increase in AA levels resulted pri-
marily from decreased degradation. The rate limiting step in BCAA deg-
radation is the branched chain α-ketoacid dehydrogenase (BCKD) [32].
Changes in β-oxidation of fatty acids have been associated with altered
mitochondrial BCKD activity and insulin resistance; and it is known that
ﬁsh oil alters mitochondrial β-oxidation of fatty acids [33]. Thus, a pos-
sible model of indirect regulation of glucose homeostasis may be that
PUFA can modulate the plasma concentrations of AA by altering their
degradation; and in turn AA can regulate insulin resistance and insulin
secretion. It has been shown that fatty acids modify the effects of
BCAA on insulin action [34] Lu et al. investigated the effects of ﬁsh oil
on plasma metabolites and hepatic gene expression [35]. They found
that ﬁsh oil activated PPARα in the live and altered gene expression of
185S.E. Karakas et al. / BBA Clinical 5 (2016) 179–185the enzymes involved BCAA degradation as well as plasma levels of sev-
eral of the AA listed in Table 2 of ourmanuscript. A recent article in dys-
lipidemic and control human subjects also demonstrated that ﬁsh oil
treatment regulated the genes involved in AA metabolism [36]. Thus
emerging evidence supports the regulatory role of PUFA on AAmetabo-
lism in animal models and humans.
Finally, changes in sulfur containing AA are also noteworthy. Fish
and soybean oils decreased cysteine by 57% and 30% respectively; ﬁsh
oil also increased methionine sulfoxide by 24%. These ﬁndings are
consistentwith increased oxidative stress during increased PUFA intake.
Increased oxidative stress is known to cause insulin resistance by in-
creasing inﬂammation [37].
In summary, our ﬁndings suggest the novel possibility that dietary
PUFA may alter glucose homeostasis indirectly, secondary to its effects
on the AA metabolism. Alternatively, alterations in AA metabolism can
be the consequence of the PUFA-induced changes in insulin sensitivity.
The small sample size and wide range of BMI of the study subjects
reduced the power for detection of several of the changes in glucose
homeostasis parameters. Further research is necessary to investigate
the potential mechanisms and to understand if these ﬁndings manifest
outside the context of PCOS.
Transparency document
The Transparency documents associated with this article can be
found, in online version.
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